• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.

作者信息

Cossmann Anne, Hoffmann Markus, Stankov Metodi V, Lürken Karsten, Morillas Ramos Gema, Kempf Amy, Nehlmeier Inga, Pöhlmann Stefan, Behrens Georg M N, Dopfer-Jablonka Alexandra

机构信息

Department of Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany.

Dialysis Center Eickenhof, Langenhagen, Germany.

出版信息

Lancet Infect Dis. 2024 Mar;24(3):e145-e146. doi: 10.1016/S1473-3099(23)00783-1. Epub 2024 Jan 8.

DOI:10.1016/S1473-3099(23)00783-1
PMID:38211602
Abstract
摘要

相似文献

1
Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.德国血液透析患者接种BNT162b2 XBB.1.5疫苗后的免疫反应。
Lancet Infect Dis. 2024 Mar;24(3):e145-e146. doi: 10.1016/S1473-3099(23)00783-1. Epub 2024 Jan 8.
2
Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.BNT162b2 XBB.1.5疫苗接种后的体液免疫和细胞免疫反应。
Lancet Infect Dis. 2024 Jan;24(1):e1-e3. doi: 10.1016/S1473-3099(23)00690-4. Epub 2023 Nov 20.
3
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.接受 BNT162b2 BA.4/5 或 mRNA-1273 BA.1 二价疫苗接种的终末期肾病患者体内针对奥密克戎变异株的中和抗体。
Nat Commun. 2023 Sep 27;14(1):6041. doi: 10.1038/s41467-023-41678-9.
4
Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study.印度尼西亚日惹地区接受血液透析的终末期肾病患者中 COVID-19 BNT162b2 加强疫苗的免疫原性和安全性：一项队列前瞻性研究。
BMC Nephrol. 2023 May 30;24(1):151. doi: 10.1186/s12882-023-03218-x.
5
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.瑞典针对单价XBB.1.5适应性BNT162b2 mRNA加强针的体液免疫反应。
Lancet Infect Dis. 2024 Feb;24(2):e80-e81. doi: 10.1016/S1473-3099(23)00779-X. Epub 2024 Jan 5.
6
Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2.在接受BNT162b2疫苗接种后，血液透析患者对关注变异株B1.1.7和B.1.351的体液免疫受损，但细胞免疫反应显著。
J Am Soc Nephrol. 2021 Nov;32(11):2725-2727. doi: 10.1681/ASN.2021050672.
7
Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study.血液透析患者接种 mRNA 基于 SARS-CoV-2 疫苗后第一剂和第二剂后 IgG 抗体水平的时间依赖性演变：一项多中心研究。
Nephrol Dial Transplant. 2022 Jan 25;37(2):375-381. doi: 10.1093/ndt/gfab293.
8
Similar humoral immune responses in peritoneal dialysis and haemodialysis patients after two doses of the SARS-CoV-2 vaccine BNT162b2.两剂 SARS-CoV-2 疫苗 BNT162b2 接种后腹膜透析和血液透析患者的相似体液免疫反应
Perit Dial Int. 2022 Jan;42(1):100-101. doi: 10.1177/08968608211055631. Epub 2021 Nov 9.
9
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.COVID-19 与透析：临床影响、免疫反应、预防和治疗。
Kidney Int. 2022 May;101(5):883-894. doi: 10.1016/j.kint.2022.01.022. Epub 2022 Feb 14.
10
Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.与透析患者和健康儿童相比，SARS-CoV-2 mRNA BNT162b2 疫苗在儿科肾移植受者中的体液和细胞免疫反应。
Pediatr Nephrol. 2023 Jul;38(7):2199-2208. doi: 10.1007/s00467-022-05813-w. Epub 2022 Dec 2.

引用本文的文献

1
Humoral Immune Responses in Dialysis Patients After mRNA Omicron JN.1 Vaccination.mRNA奥密克戎JN.1疫苗接种后透析患者的体液免疫反应
Kidney Med. 2025 Jul 7;7(9):101067. doi: 10.1016/j.xkme.2025.101067. eCollection 2025 Sep.
2
Antibody and B-Cell Responses to PHH-1V81 XBB.1.16-Adapted SARS-CoV-2 Booster Vaccination Are Associated With Variant Neutralization.针对PHH-1V81 XBB.1.16适应性严重急性呼吸综合征冠状病毒2加强疫苗接种的抗体和B细胞反应与变体中和相关。
J Med Virol. 2025 Sep;97(9):e70583. doi: 10.1002/jmv.70583.
3
The XBB.1.5 mRNA booster vaccine does not significantly increase the percentage of XBB.1.5 mono-reactive T cells.
XBB.1.5 mRNA加强疫苗不会显著增加XBB.1.5单反应性T细胞的百分比。
Front Immunol. 2025 Mar 12;16:1513175. doi: 10.3389/fimmu.2025.1513175. eCollection 2025.
4
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses.针对不同免疫功能低下状况个体的新型冠状病毒mRNA疫苗纵向免疫原性队列研究：免疫反应的异质性及奥密克戎适应性加强剂量的关键作用
EBioMedicine. 2025 Mar;113:105577. doi: 10.1016/j.ebiom.2025.105577. Epub 2025 Feb 4.
5
Impaired Hepatitis B and COVID-19 vaccination responses show strong concordance in hemodialysis patients with end stage renal disease.在终末期肾病血液透析患者中，乙肝疫苗和新冠疫苗接种反应受损表现出高度一致性。
Eur J Med Res. 2025 Jan 16;30(1):34. doi: 10.1186/s40001-025-02274-3.
6
Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients.肝移植受者接种XBB.1.5加强针后对SARS-CoV-2 XBB.1.5和JN.1变体的免疫反应
Viruses. 2024 Dec 19;16(12):1942. doi: 10.3390/v16121942.
7
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial.为免疫功能低下人群优化 COVID-19 疫苗接种方案（BOOST-IC）：一项适应性随机对照临床试验的研究方案。
Trials. 2024 Jul 17;25(1):485. doi: 10.1186/s13063-024-08315-2.